Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590525 · ClinicalTrials.gov registry record
Inflammation as a Predictor in Cardioversion of Atrial Fibrillation
A clinical trial, sponsored by Creighton University.
- Completed
- Registry status
- 45
- Enrollment target
NCT00590525: Completed study, sponsored by Creighton University.
NCT00590525 is a clinical trial that has completed, run by Creighton University. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590525 has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial fibrillation who are planning to undergo cardioversion to determine what sort of relationship exists between CRP levels and atrial fibrillation. We will then look at success rates of converting atrial fibrillation to normal sinus rhythm, compared to patients' CRP levels.
Interventions
- PROCEDURE Cardioversion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-06 |
What the finished NCT00590525 record still lists
NCT00590525 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cardioversion is the first listed.
NCT00590525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00590525 about?
NCT00590525 is a clinical study titled "Inflammation as a Predictor in Cardioversion of Atrial Fibrillation". The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial ...
What is the current status of trial NCT00590525?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2004-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00590525?
The interventions under investigation include: Cardioversion (PROCEDURE).
Who is sponsoring clinical trial NCT00590525?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia